333 related articles for article (PubMed ID: 27478111)
1. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
[TBL] [Abstract][Full Text] [Related]
2. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
3. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.
Aly A; Onukwugha E; Woods C; Mullins CD; Kwok Y; Qian Y; Arellano J; Balakumaran A; Hussain A
BMC Med Res Methodol; 2015 Aug; 15():65. PubMed ID: 26286392
[TBL] [Abstract][Full Text] [Related]
4. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
5. Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease.
Mortimer JE; Schulman K; Kohles JD
Clin Breast Cancer; 2007 Aug; 7(9):682-9. PubMed ID: 17919348
[TBL] [Abstract][Full Text] [Related]
6. Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study.
Sato S; Tomitori H; Okawa A; Akano K
Int J Clin Oncol; 2023 Sep; 28(9):1227-1235. PubMed ID: 37314600
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
8. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
[TBL] [Abstract][Full Text] [Related]
9. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
10. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
12. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
13. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.
Broder MS; Gutierrez B; Cherepanov D; Linhares Y
Support Care Cancer; 2015 Jan; 23(1):237-47. PubMed ID: 25270847
[TBL] [Abstract][Full Text] [Related]
14. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
15. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
Saad F
Clin Prostate Cancer; 2005 Jun; 4(1):31-7. PubMed ID: 15992459
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
18. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
19. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
20. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
